A Randomized Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Different Single-Dose Subcutaneous Treatments of SAR236553/REGN727 in Healthy Subjects.

Trial Profile

A Randomized Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics After Different Single-Dose Subcutaneous Treatments of SAR236553/REGN727 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2013

At a glance

  • Drugs Alirocumab (Primary)
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Feb 2012 Company (Regeneron Pharmaceuticals) added as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top